Compare Crocs, Inc. (CROX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Smith & Nephew plc — how do they compare? Crocs, Inc. trades at $116.68 (market cap $5.53B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 2× Crocs, Inc.'s market cap, and Smith & Nephew plc pays a 2.95% dividend while Crocs, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and Smith & Nephew plc for 120 Days on average.
| CROX | SNN | |
|---|---|---|
Market Cap | $5.53B | $11.10B |
Volume | 967,176 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $37.17 |
52-Week Low | $73.39 | $26.42 |
Typical Hold Time | 96 Days | 120 Days |
Enterprise Value | $7.04B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CROX trades at $115.20, down 4.18% amid bearish technical signals, though valuation metrics appear attractive with a P/E of 10.23 and P/S of 1.46. Recent earnings beats and a 51% analyst buy rating support fundamental strength, but 2025 net income turned negative due to tax impacts. The stock faces resistance near $116-119 with support at $114.
Outlook remains mixed: strong brand positioning and earnings momentum contrast with technical weakness and recent profitability challenges. The consensus price target of $136.78 suggests 19% upside, but investors should weigh competitive pressures and consumer spending volatility against valuation appeal.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
